HIGHLIGHTS
- who: Peng Li from the (IRCCS), Italy Emory University, United States have published the paper: Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy, in the Journal: (JOURNAL)
- what: Frontiers in Oncology | www.frontiersin.org Herein, the authors provide extensive evidence that patients with HER2 and Luminal B might benefit from androgens combined with ICR-targeted therapies. The authors reported the levels of androgens (testosterone and DHT) and ICRs of T_cells originated from BRCA subtypes, and found that androgens were significantly decreased in HER2 and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.